Open Label Non-comparative Clinical Trial of Tigecycline in Patients With Catheter Infection

PHASE4CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

January 31, 2007

Primary Completion Date

May 31, 2008

Study Completion Date

May 31, 2008

Conditions
Staphylococcal Infections
Interventions
DRUG

Tigecycline

All patients will receive tigecycline infusions approximately every 12 or 24 hours. The usual regimen of tigecycline is (an initial intravenous (IV) dose of 100 mg followed by 50 mg approximately every 12 hours). Patients with severe hepatic dysfunction may, at the investigator's discretion with CPL Associates approval (call enrollment hotline) may be given a total daily dose of 50 mg (one 50 mg dose or 25 mg approximately every 12 hours). Tigecycline infusions will be administered over approximately 30 minutes in 100 mL of normal saline.

Trial Locations (3)

21502

CPL Associates Investigational Site, Cumberland

30060

CPL Associates Investigational Site, Marietta

35801

CPL Associates Investigational Site, Huntsville

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

Wyeth is now a wholly owned subsidiary of Pfizer

INDUSTRY

lead

CPL Associates

OTHER

NCT00419991 - Open Label Non-comparative Clinical Trial of Tigecycline in Patients With Catheter Infection | Biotech Hunter | Biotech Hunter